iQ-007 Zebrafish Screening Reveals Positive Results in Other Neurodegenerative Diseases

Princeton, NJ, June 21 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech  company dedicated to the development of new epilepsy and pain management therapeutics, is proud to announce that its lead asset iQ-007, has shown positive results in a zebrafish screening for a series of neurodegenerative diseases.

iQ-007 is a positive allosteric modulator of the EAAT2 transporter and represents a novel approach to treat neurodegenerative diseases.  Based on the positive results of iQ-007 for epilepsy and the successful completion of the ETSP program, iQure decided to explore the general mechanism of action of iQ-007 in other neurodegenerative diseases. Over the last few months, iQ-007 was tested in a series of in vivo zebrafish models of many high medical need neurodegenerative conditions, including Alzheimer’s disease and Parkinson’s disease. iQ-007 produced statistically significant effects in all models, matching, or in some cases exceeding positive control results, underpinning the importance of the role of EAAT2 in neurodegenerative diseases. “This excellent set of results supports iQ-007 as a Platform Therapeutic with the potential for helping patients who are suffering from these debilitating diseases.” said Pawel Zolnierczyk, iQure CEO. “We are looking forward to continuing to explore iQ-007’s clinical development potential and optimum market positioning.”

About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies.

For more information about supporting iQure’s initiatives, contact iQure CEO Pawel Zolnierczyk at pawel.zolnierczyk@iqurepharma.com.

Initial iQ-007 IND-Enabling Tox Results Accelerate Prep for First in Human Phase 1 Study

Princeton, NJ, March 19, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-007, a novel anticonvulsant compound, has completed the first stage of pivotal IND-enabling Tox studies in rodent and non-rodent species.

“The recent results confirm what we already know about this exciting compound,” said Pawel Zolnierczyk, CEO. “We’re one step closer to bringing this effective therapeutic to a clinic trial, with the potential to significantly improve patients’ quality of life. Results of recent toxicological studies show that iQ-007 unique mechanism of action as a Positive Allosteric Modulator (PAM) of the EAAT2 neurotransporter, is a very promising therapeutic strategy, ‘triggering a human natural safety mechanism’ that allows for more efficient clearance of excess glutamate which in turn prevents neurotoxicity and seizures.”

iQ-007 is well tolerated and continues to demonstrate an impressive safety profile. iQure Pharma is looking forward to completing the IND-enabling tox study series, which will accelerate the preparation of the First in Human Phase 1 study.

About iQure Pharma:

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies based on a revolutionary glutamate-clearance platform for treating neurodegenerative conditions including neuro-inflammation.

For more information, please contact pawel.zolnierczyk@iqurepharma.com.

iQure Pharma Awarded Its First Patent for iQ-008, a Novel Analgesic Compound to Treat Neuropathic Pain

Princeton, NJ, January 23, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-008, a novel analgesic compound dedicated to treating neuropathic pain, has been awarded a patent.

“We are thrilled with the patent granted for iQ-008,” said iQure Chief Executive Officer Pawel Zolnierczyk.  “This is an important step in the process of commercializing this promising asset for the treatment of Pain. Patent protection is pivotal to maintaining the value of our assets. With the awarding of this patent, we have expanded its protection and strengthened its potential on the market.”

iQ-008 is effective in critical in vivo studies against the “gold-standard,” but without the typical CNS side effects. Through its unique mechanism, focused on simultaneous action on more than one pain relevant molecular target, iQ-008 displays strong efficacy with minimal risk of side effects. The compound is also being vigorously tested by the NIH in its high profile Preclinical Screening Platform for Pain (PSPP), as part of the HEAL Initiative.

iQure researchers developed iQ-008 as a therapeutic for neuropathic pain, in response to the more than 25 million Americans who live with chronic pain and are forced to rely solely on potentially addictive opioid medications for pain management.

About iQure Pharma:

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies based on a revolutionary glutamate-clearance platform for treating neurodegenerative conditions including neuro-inflammation.

For further information, please contact pawel.zolnierczyk@iqurepharma.com.